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Introduction
According to the National  Academy of Sciences, 
clinical practice guidelines are “statements that include 
recommendations intended to optimize patient care” (1). 
Guidelines are informed by a systematic review of available 
evidence, and should assess the benefits and harms of each 
intervention, as well as of alternative options. 
A large number of clinical practice guidelines are 
available in oncology, most of them produced by 
International or National scientific societies. Due to the 
extremely rapid evolution of this field of medicine, most 
guidelines need to be updated annually or, in some cases 
[e.g., U.S. National Comprehensive Cancer Network 
(NCCN)], even more frequently.
The relationship between cancer and host and, 
specifically, with the immune system has been an active 
field of investigation since many decades, leading to 
the introduction of commonly used approaches such as 
cytokines-based treatments in renal cell carcinoma (2) and 
cutaneous melanoma (3), or Bacillus Calmette-Guérin 
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instillation for non-muscle-invasive bladder cancer after 
endoscopic resection (4). However, other immunologic 
strategies such as vaccination against cancer-specific 
antigens failed to show benefits in solid tumors (5) and, 
even if cytokines are still considered treatment options by 
most guidelines in specific types of tumors, their use has 
been largely reduced by the introduction of more effective 
and less toxic treatments (2).
More recently, the discovery that cancer cells can 
exploit some immune inhibitory receptors such as 
cytotoxic T-lymphocyte associated protein 4 (CTLA-4) 
and programmed death-1 (PD-1) and its ligands (PD-L1 
and PD-L2) to escape immune system surveillance, led the 
way to the development of specific monoclonal antibodies. 
Following the results of clinical trials testing their efficacy, 
these molecules, known as immune checkpoint inhibitors, 
are being increasingly used for the treatment many solid 
tumors, including lung cancer. 
In this paper we reviewed the recommendations about 
the use of immune checkpoint inhibitors in the latest 
version of four different lung cancer clinical practice 
guidelines, three made by Scientific National [American 
Society of Clinical Oncology (ASCO); Italian Association 
of Medical Oncology (AIOM)] and International [European 
Society of Medical Oncology (ESMO)] Societies and one by 
not-to-profit alliance of 27 leading American cancer centers 
(NCCN) (Table 1).
ASCO guidelines
The latest ASCO Guideline update on systemic therapy 
for stage IV non-small cell lung cancer (NSCLC) has 
been published online in August 2017 (6) and is based 
on the former version published in 2015 (7). This update 
was made using a “signals” approach that outlines formal 
criteria for identifying new, practice-changing data (8). By 
doing so, two major categories of changes were recognized 
as potential signals: potentially invalidating changes of 
evidence (opposing findings, evidence of substantial harm, 
evidence of superiority of a new treatment) and major 
changes in evidence (important changes in efficacy but not 
opposing findings, expansion of evidence of a treatment, 
important caveats). The expert panel reviewed the protocol 
used for the previous systematic review, then completed a 
formal literature review and sook for Expert Panel input 
and finally chose the updating option. Recommendations 
were developed, in part, using the Guidelines Into Decision 
Support (GLIDES) methodology (9) and accompanying 
BRIDGE-Wiz softwareTM. By doing so, recommendations 
were defined as evidence-based or based on either formal or 
informal consensus. The strength of each recommendation 
was rated as strong, moderate or weak, while the strength of 
evidence was rated as high, intermediate, low or insufficient. 
Finally the potential risk of bias was also rated.
As for first-line treatment, the panel considered the 
randomized phase III trial comparing pembrolizumab, 
a humanized monoclonal antibody against PD-1, vs. 
investigator’s choice of platinum-based chemotherapy, in 
patients who had previously untreated advanced NSCLC 
with PD-L1 expression on at least 50% of tumor cells, and 
no sensitizing mutation of the epidermal growth factor 
receptor (EGFR) gene or translocation of the anaplastic 
lymphoma kinase (ALK) gene (10). The primary endpoint 
of the trial was progression-free survival (PFS). Median 
PFS was 10.3 months in the pembrolizumab group versus 
6.0 months in the chemotherapy group [hazard ratio (HR) 0.50; 
95% confidence interval (95% CI), 0.37 to 0.68; P<0.001]. 
Pembrolizumab was also associated with a significant benefit 
in overall survival (HR 0.60; 95% CI, 0.41 to 0.89; P=0.005), 
in response rate (44.8% vs. 27.8%, with a longer duration 
of response), and in toxicity. Based on these results, ASCO 
guidelines suggest the use of single-agent pembrolizumab as 
first-line treatment in patients with advanced NSCLC, without 
EGFR activating mutations, ALK or ROS1 rearrangements and 
high PD-L1 expression (tumor proportion score-TPS ≥50%), 
in the absence of contraindications to immune checkpoint 
blockade. This recommendation is strong as it is evidence-
based, with high quality of evidence.
In the second-line setting, recommendations are 
based on the randomized phase III trials comparing anti-
PD-1 (nivolumab or pembrolizumab) or anti-PD-L1 
(atezolizumab) monoclonal antibodies vs. docetaxel 
(11-14) in patients with advanced NSCLC who had 
previously failed first-line platinum-based chemotherapy. 
Trials of nivolumab and atezolizumab did not select 
patients according to PD-L1 expression, while trial of 
pembrolizumab was limited to patients with positive PD-L1 
expression. In all those trials, primary endpoint was overall 
survival, and immune checkpoint inhibitors demonstrated 
a significant benefit compared to chemotherapy. Patients 
with EGFR mutation or ALK rearrangement were included 
in the trials, but subgroup analysis did not show a clear 
superiority for immune checkpoint inhibitors compared 
to chemotherapy (11-14). According to ASCO guidelines, 
the use of checkpoint inhibitors is suggested in NSCLC 
advanced patients without EGFR mutations or ALK and 
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ROS1 rearrangements who did not receive pembrolizumab 
in the first-line setting. Coherently with inclusion criteria 
of the respective pivotal trials, patients with positive PD-L1 
staining (TPS ≥1% with 22C3 assay) can be treated with either 
single-agent pembrolizumab, nivolumab or atezolizumab 
(strong evidence-based recommendation with high quality 
of evidence). Those with negative (TPS <1%) or unknown 
PD-L1 expression should receive nivolumab or atezolizumab 
monotherapies (strong evidence-based recommendation with 
high quality of evidence). The preferred second-line option 
for those treated with first-line pembrolizumab is standard 
platinum-based chemotherapy and, even if the quality of 
evidence is low (based on informal consensus among panelists, 
given the absence of trials specifically conducted in this 
setting), the recommendation is strong.
For patients with EGFR sensitizing mutations, already 
treated with specific tyrosine kinase inhibitors (TKIs) 
and platinum-based chemotherapy, the ASCO panel 
underlines that there are insufficient data to recommend 
immunotherapy in preference to chemotherapy (pemetrexed 
or docetaxel). This recommendation is weak and based on 
informal consensus among panelists as available evidence is 
insufficient, based on the small number of patients included 
in subgroup analyses.
Table 1 Recommendations about the use of immune checkpoint inhibitors in patients with lung cancer, according to the latest version of four 
different lung cancer clinical practice guidelines (as of January 2018)
Drug Disease Line of 
treatment
ASCO guidelines ESMO guidelines NCCN 
guidelines
AIOM guidelines
Atezolizumab Advanced 
NSCLC
Platinum- 
pretreated 
Positive strong 
recommendation 
with high quality of 
evidence
Not included Category 1 Not included
Durvalumab Locally 
advanced 
NSCLC
After chemo-
radiotherapy
Not included Not included Category 
2A
Not included
Nivolumab Advanced 
squamous 
NSCLC
Platinum-
pretreated
Positive strong 
recommendation 
with high quality of 
evidence
Grade A, level of 
evidence 1; MCBS: 5 
points
Category 1 Positive strong 
recommendation, 
low quality of 
evidence
Nivolumab Advanced 
nonsquamous 
NSCLC
Platinum-
pretreated
Positive strong 
recommendation 
with high quality of 
evidence
Grade B, level of 
evidence 1; MCBS: 5 
points
Category 1 Positive strong 
recommendation, 
low quality of 
evidence
Nivolumab +/− 
Ipilimumab
Advanced 
SCLC
Second-line 
treatment
Not included Not included Category 
2A
Not included
Pembrolizumab PD-L1 positive 
(≥50%) 
advanced 
NSCLC
First-line 
treatment
Positive strong 
recommendation 
with high quality of 
evidence
Not included Category 1 Positive strong 
recommendation, 
low quality of 
evidence
Pembrolizumab 
plus platinum/
pemetrexed
Advanced 
NSCLC
First-line 
treatment
Not included Not included Category 
2A
Not included
Pembrolizumab PD-L1 
positive (≥1%) 
advanced 
NSCLC
Platinum-
pretreated
Positive strong 
recommendation 
with high quality of 
evidence
Grade A, level of 
evidence 1; MCBS: 5 
points (PD-L1 ≥50%) and 
3 points (PD-L1 ≥1%)
Category 1 Positive strong 
recommendation, 
low quality of 
evidence
ASCO, American Society of Clinical Oncology; ESMO, European Society of Medical Oncology; NCCN, National Comprehensive Cancer 
Network; AIOM, Italian Association of Medical Oncology; NSCLC, non-small cell lung cancer; MCBS, Magnitude of Clinical Benefit Scale; 
SCLC, small cell lung cancer; PD-L1, programmed death ligand 1.
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In the immunotherapy field, the ASCO panel listed 
several issues suffering from lack of data and/or insufficient 
evidence: among those issues, contraindications to 
immune checkpoint inhibitors, their combinations with 
other checkpoint inhibitors or with chemotherapy, the 
treatment of patients who experienced toxicities during 
immunotherapy, the full utility of biomarker tests for 
PD-L1 expression.
The latest ASCO guideline on treatment of patients 
with small-cell lung cancer was published in 2015. 
Consequently, it does not contain any recommendation on 
immunotherapy.
ESMO guidelines
In 2017 ESMO published clinical practice guidelines for 
early stage and locally advanced NSCLC (15), while those 
on advanced NSCLC go back to 2016 (16) with an e-update 
in June 2017 (17). 
 ESMO guidelines are produced and updated by ESMO 
Guidelines Committee (GLC). Differently from other 
guidelines, these documents contain, beside thematic 
sessions, figures and algorithms, a personalized medicine 
synopsis table as well as a table with the ESMO-Magnitude 
of Clinical Benefit Score (MCBS) (18,19) for all the newly 
European Medicines Agency (EMA) approved therapies or 
indications. 
ESMO MCBS is a dynamic tool developed to assess the 
magnitude of clinical benefit of new and effective cancer 
therapies. To reach this goal, a dual rule was implemented 
taking into account both the lower limit of the 95% CI 
for HR compared to a specified threshold value and the 
observed absolute difference in treatment outcomes for 
a given trial compared with the minimum absolute gain 
considered as beneficial. This scale is composed by two 
parts: part 1 evaluates treatments with curative intent (such 
as adjuvant chemotherapy) and is graded A, B or C where A 
and B represent the higher levels of clinical benefit; part 2 
evaluates treatments without curative intent and is graded 5, 
4, 3, 2, 1 where grades 5 and 4 represent the higher level of 
proven clinical benefit. MCBS calculations are performed 
by the Subject Editor who should involve the guidelines 
lead author to check and validate the scores produced. 
Moreover these scores are reviewed and approved by the 
guidelines steering committee, the MCBS Working Group 
and the ESMO President’s Council.
Recommendations are accompanied by proper level of 
evidence and grade of recommendation according to the 
adapted Infectious Disease Society of America-United 
States Public Health Service Grading System (20).
Guidelines on early stage and locally advanced 
NSCLC do not include any recommendation about 
immunotherapy, given that, when they were produced and 
published, results of the PACIFIC study on durvalumab 
after chemoradiotherapy in stage III NSCLC were not 
available yet (21). In the PACIFIC trial, patients with stage 
III NSCLC who did not have disease progression after 
platinum-based chemo-radiotherapy were randomized to 
durvalumab (anti-PD-L1 monoclonal antibody) or placebo. 
The co-primary endpoints were PFS and overall survival. 
Median PFS was 16.8 months with durvalumab versus 
5.6 months with placebo (HR 0.52; 95% CI, 0.42 to 0.65; 
P<0.001). Durvalumab was also associated with a significant 
improvement in the response rate, in the duration of 
response and in the time to death or distant metastasis, 
while mature overall survival data are still not available. 
Indeed, in the advanced disease setting, recommendations 
on immunotherapy are made for second-line treatment 
and beyond. In this setting, pembrolizumab at a dosage of 
2 mg/kg every 3 weeks is considered a second- or third-line 
option (grade A recommendation, level of evidence I). As 
the phase III trial showed a superior outcome in patients 
with high PD-L1 expression (>50%), the ESMO-MCBS 
version 1.0 differs between those with PD-L1 >1% (score: 3) 
as compared to those with PD-L1 >50% (score: 5). 
Nivolumab is also recommended in platinum-pretreated 
patients in squamous histology (grade A, level I; ESMO-
MCBS score: 5). However, in nonsquamous histologies, 
nivolumab is considered an option in pretreated patients 
(grade B, level I, ESMO-MCBS score: 5). Moreover, 
the panel underlines that, as it should be administered in 
second-line setting, only patients with PD-L1 positive 
tumors extract an OS benefit compared to docetaxel 
(grade B, level I), while those with PD-L1 negative tumors 
have similar OS with nivolumab and docetaxel, even if 
immunotherapy has a more favourable toxicity profile than 
chemotherapy (grade II, level A). No recommendations 
are provided on the use of pembrolizumab in the first-line 
setting.
ESMO Clinical Practice Guidelines on small cell lung 
cancer (SCLC) were published in 2013 and do not contain 
any recommendation on immunotherapy (22).
NCCN guidelines
As previously reported, NCCN Guidelines are evidence-
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based consensus-driven documents developed by a panel of 
members from 27 NCCN Member Institutions (23). Each 
guideline undergoes at least yearly an Institutional Review 
by clinical cancer experts from Member Institutions, even 
if interim Panel meetings are conducted throughout the 
year as needed. These guidelines are intended to assist all 
individuals who impact the decision making in cancer care 
also including payers, along with healthcare professionals 
and patients, given the fact that such documents are 
developed for an insurance-based national healthcare 
system.
NCCN categories of recommendations are based on 
both the level of clinical evidence available and the degree 
of consensus among the panel. The level of evidence 
depends upon three factors: extent of data, consistency of 
data, and quality of data. The degree of consensus is based 
on the percentage of panel votes. The cost of intervention is 
not formally considered even if, in some cases when robust 
data on pharmacoeconomics studies are available, panels 
may consider it. 
NCCN categories are defined as: category 1, when 
based upon high-level evidence, with uniform consensus 
that the intervention is appropriate; category 2A, when 
based upon lower-level evidence but with still uniform 
consensus on appropriateness; category 2B, based upon the 
same level of evidence as the latter with NCCN consensus 
on appropriateness although not uniform; category 3 
when, despite any level of evidence, there is major NCCN 
disagreement that the intervention is appropriate. In these 
guidelines, uniform consensus requires that at least 85% of 
Panel votes. The “NCCN consensus” required for category 
2B is present when at least 50% (but less than 85%) of 
Panelists vote in favor of a recommendation. Finally, 
disagreement requires at least 3 Panel Members (from 
different Institutions) to vote.
The latest NCCN Clinical Practice Guideline on NSCLC 
has been published online on December 19th 2017 (24). 
Indications to immunotherapy are present both for the 
locally advanced setting and the metastatic one. The 
panel recommend as category 2A durvalumab (an anti-
PD-L1 monoclonal antibody) as consolidation therapy 
for up to 12 months for patients with stage III NSCLC 
not progressing after definitive chemoradiation therapy. 
This recommendation is based on the results of the phase 
III PACIFIC trial (21). In the advanced setting the panel 
recommends nivolumab treatment as subsequent therapy 
in NSCLC patients progressing on or after first-line 
chemotherapy. This category 1 recommendation included 
both squamous and non-squamous histologies even if, in 
this latter group, the panel underlines the presence of a 
complementary diagnostic biomarker test assay that could 
help clinicians in choosing which patients may benefit most 
from immunotherapy. In this setting, NCCN Guidelines 
recommend also pembrolizumab (in patients with NSCLC 
and PD-L1 expression levels of 1% or more—category 1) or 
atezolizumab, independently of PD-L1 expression (category 1).
When treating patients in the first-line setting, NCCN 
recommends pembrolizumab treatment in patients whose 
tumors show high PD-L1 expression (more or equal to 50%) 
and without oncogene addiction (category 1). In this view, 
the panel explicitly recommends immunohistochemistry 
(IHC) testing of PD-L1 before first-line treatment in all 
patients with advanced NSCLC with negative or unknown 
tests results for known oncogenes (category 2A).
For patients with advanced untreated non-squamous or 
not otherwise specified (NOS) NSCLC, NCCN guidelines 
recommend combination treatment with pembrolizumab 
plus carboplatin plus pemetrexed, based on the results of 
a cohort of a randomized phase 2 trial that led to the FDA 
approval of this combination (category 2A) (25). Notably, 
for this indication, patients need not to be selected on the 
basis of PD-L1 expression levels. 
NCCN guidelines on SCLC have been published, in 
their latest version, in September 2017 (26). 
The panel recommends second-line therapy with 
nivolumab or nivolumab plus ipilimumab in patients with 
SCLC relapsed 6 months or less after primary treatment as 
category 2A. This recommendation is based on the results 
of a phase I/II trial (27).
AIOM guidelines
The Italian Association of Medical Oncology (AIOM) 
guidelines are made by using an adapted GRADE 
methodology (28). Every year, synchronously with AIOM 
annual meeting, guidelines are updated and published on 
the society website. Every recommendation is based on 
a clinical question formulated using PICO (population, 
intervention, control, and outcomes). Recommendations are 
graded on a four levels scale: strong positive, weak positive, 
weak negative, and strong negative. Quality of evidence is 
judged as high, moderate, weak, or very weak.
Notably, these documents contain recommendations 
that could be implemented in the national context and, 
by doing so, encompass only interventions that have been 
approved for use in clinical practice by Italian authorities 
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and reimbursed by National Health System. The latest 
version of AIOM lung cancer guidelines has been published 
in October 2017 (29).
Wi t h  r e g a r d  t o  i m m u n o t h e r a p y,  t h e  p a n e l 
recommendation about the use of pembrolizumab as first-
line monotherapy in patients with advanced NSCLC and 
high PD-L1 expression (≥50%) is strong, even if the quality 
of the evidence is considered low. Indeed, the authors 
underline potential bias on the Keynote-024 trial such as 
the lack of blinding, the sponsor participation in trial design 
as well as in data analysis and manuscript writing, and the 
early study interruption (even if based on pre-specified 
interim analysis).
In the second-line setting, nivolumab as well as 
pembrolizumab (in patients with ≥1% of PD-L1 positive 
cells) should be considered the first treatment option in 
both squamous and non-squamous NSCLC patients. To 
date, atezolizumab is approved by European Medicines 
Agency, but it is still not reimbursed for use in clinical 
practice in Italy. The panel evaluated the global quality of 
evidence in this context as low, but strongly recommends 
this intervention as compared to docetaxel chemotherapy.
No recommendations on immunotherapy and SCLC are 
present, as checkpoint inhibitors are not registered with this 
indication neither in Europe nor in Italy.
Discussion
Clinical practice guidelines represent an essential tool that 
helps clinicians in the decision making process, especially 
in rapidly evolving fields, such as oncology. In this context, 
different international as well as national scientific oncology 
societies produce documents with the aim of implementing 
cancer care and distributing knowledge among physicians as 
well as health care professionals.
The crucial role of updated guidelines is particularly evident 
when innovative interventions, such as immune checkpoint 
inhibitors in lung cancer, are made available. As all novelties 
could bring, along with advances in care, unresolved issues or 
debated questions on their appropriate use, guidelines have the 
important role of widely harmonizing their adoption.
Because guidelines greatly differ in methodology, 
formal comparisons between them are incorrect. However, 
strengths and weaknesses of different documents deserve a 
discussion.
ASCO guidelines are made using a well-described 
methodology making them, in principle, a robust tool for 
clinical decision making. However, they lack a continuous 
or time-predefined updating, and, at least at some time 
points, their applicability in this rapid evolving field is 
substantially limited.
ESMO guidelines suffer of the same limitations of 
ASCO ones, even if online updates are more frequent. 
Although ESMO members have recently increased also 
outside Europe, ESMO documents are intended to be used 
in the European countries and for this reason they include 
EMA-approved interventions only. Of note, by using the 
ESMO MCBS, they include an evaluation of the value of 
each intervention. Even if this tool should be viewed as an 
effort to introduce some elements from the public health 
perspective in an otherwise purely clinical document, there 
are some great limitations that need to be underlined. 
As already reported by Sobrero and colleagues, this scale 
adopts a mono-dimensional, protocol-driven approach, 
focused on the evaluation of single randomized trial 
results, thus missing the complex, multidimensional and 
sometimes indirect evidence available for many drugs (30). 
Other limitations of the first ESMO MCBS version include 
the use of fixed HR thresholds for classifying drugs (favoring 
small trials with more variable HR estimates) and the lack 
of toxicity-driven downgrading of the score when an OS 
benefit is observed. As the clinical benefit is defined by the 
integration of efficacy, toxicity and convenience, the ESMO 
MCBS lack the latter two dimensions by focusing on 
efficacy only. However, since immune checkpoint inhibitors 
always demonstrated a favorable toxicity profile as compared 
to chemotherapy in all available randomized trial, we 
acknowledge that the issue on toxicity-driven downgrading 
would not be an issue in this context. However, some of the 
above cited limitations and weaknesses have been addressed 
in the revised version (1.1) of the ESMO MCBS (19).
NCCN guidelines carry the great advantage of being 
updated every time a new intervention becomes available 
in the United States following the FDA approval. This is 
critical in an insurance-based health system such as that of 
the US where central drugs approval is extremely fast by 
limiting the need of price and reimbursement discussions. 
For this reason, these guidelines are very useful in providing 
all the possible options for a given clinical situation 
especially when taking into account novel drugs. However 
they are weaker in providing comparative tools to help 
clinicians in clinical decision making and they lack a strong 
methodologic background.
AIOM guidelines, on the contrary, are made with a 
robust methodology. They are annually updated and 
contain recommendations on all the available options for a 
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given clinical question in the Italian context. For this latter 
reason, their transferability beyond the Italian borders is the 
major limitation.
Bearing in mind all these caveats and limitations, as 
a general rule, all clinicians should make their best in 
studying and applying clinical practice guidelines, because 
their use would substantially improve homogeneity and 
appropriateness of interventions adopted in clinical practice.
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